Dendrimers and their applications
Abstract
Dendrimers are symmetric molecules; their size is within the nanoscale. Its structure is usually homogeneous and monodisperse; they are composed of a nucleus and several layers 1. The number of layers that the dendrimer has defines its generation. There are different types of dendrimers. The synthesis of these macromolecules is carried out following steps of growth and activation, and organic reactions are required to obtain their branched structure2. Although size is essential, the determining factor of toxicity in dendrimers is the charge of the surface; it has been found that the higher generation dendrimers and the cationic ones are the most toxic compared to the lower generation anionics that evaluated at low concentrations did not show any toxicity 3. The dendrimers will favor the pharmacokinetics of a drug through the dendritic structure, the generation of the dendrimer to be used, the intramolecular interaction force between the adjacent functional groups in the dendrimer, the conditions of the environment such as pH, solvent polarity, strength ionic, saline concentration or presence of counterions, among others 4. Due to dendrimers' size and surface composition, the use of dendrimers in drug delivery has been increasingly studied. There are different interaction mechanisms between drugs in dendrimers, and these can be broadly divided into simple encapsulation, electrostatic interaction, and covalent bonds 5. The use of dendrimers in ocular administration has greatly impacted the complexity of this administration route. Gene therapy has also benefited from the emergence of these molecules as it facilitates targeted therapy.
Keywords: Dendrimers, Drug delivery, Gene therapy, Pharmacokinetic, Transport System
Keywords:
Dendrimers, Drug delivery, Gene therapy, PharmacokineticDOI
https://doi.org/10.22270/jddt.v12i1-S.5307References
Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. May 21, 2014; 9(1):247. https://doi.org/10.1186/1556-276X-9-247
Walter MV, Malkoch M. Simplifying the synthesis of dendrimers: accelerated approaches. Chem Soc Rev. 2012; 41(13):4593. https://doi.org/10.1039/c2cs35062a
Gothwal A, Malik S, Gupta U, Jain NK. Toxicity and biocompatibility aspects of dendrimers [Internet]. Pharmaceutical Applications of Dendrimers. Elsevier Inc.; 2020. 251-274 p. https://doi.org/10.1016/B978-0-12-814527-2.00011-1
Díaz, C. Efecto de la modificación superficial de dendrímeros PAMAM en la cinética plasmática y formación de complejos con aplicación farmacológica. Universidad de Concepción. 2018. Available at: http://repositorio.udec.cl/jspui/handle/11594/3360
Dendrimers and their Applications as Novel Drug Delivery Carriers. J App Pharm Sci [Internet]. 2013 [citado 1 de marzo de 2021]; Available at: http://www.japsonline.com/abstract.php?article_id=1064
Huang D, Wu D. Biodegradable dendrimers for drug delivery. Mater Sci Eng C. September 2018; 90:713-27. https://doi.org/10.1016/j.msec.2018.03.002
Igartúa, D. Dendrímeros como nanotransportadores de drogas y como drogas per sé. Universidad Nacional de Quilmes. 2020; 11(4), 48-74. Available from: http://computacion-cuantica.web.unq.edu.ar/wp-content/uploads/sites/65/2016/11/D11_REV1_igartua_2020.pdf https://doi.org/10.48160/25913530di11.130
Mhlwatika Z, Aderibigbe B. Application of Dendrimers for the Treatment of Infectious Diseases. Molecules. August 31, 2018; 23(9):2205. https://doi.org/10.3390/molecules23092205
Janaszewska, Lazniewska, Trzepiński, Marcinkowska, Klajnert-Maculewicz. Cytotoxicity of Dendrimers. Biomolecules. August 1, 2019; 9(8):330. https://doi.org/10.3390/biom9080330
Sato K, Anzai J. Dendrimers in layer-by-layer assemblies: synthesis and applications. Mol Basel Switz. July 17, 2013; 18(7):8440-60.
https://doi.org/10.3390/molecules18078440
García, M. Nuevas aplicaciones de los dendrímeros en el campo de la biomedicina. (Unpublished Final Degree Project). Universidad de Sevilla. 2018. Available at: https://hdl.handle.net/11441/70937
Dias AP, da Silva Santos S, da Silva JV, Parise-Filho R, Igne Ferreira E, Seoud OE, et al. Dendrimers in the context of nanomedicine. Int J Pharm. January 2020; 573:118814. https://doi.org/10.1016/j.ijpharm.2019.118814
Chauhan A. Dendrimers for Drug Delivery. Molecules. April 18, 2018; 23(4):938. https://doi.org/10.3390/molecules23040938
Palmerson, L., Pan, J., Torchilin, V. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules. 2017; 22(9):1401-21. https://doi.org/10.3390/molecules22091401
Lazniewska J, Milowska K, Gabryelak T. Dendrimers-revolutionary drugs for infectious diseases: Dendrimers-revolutionary drugs for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. September 2012; 4(5):469-91. https://doi.org/10.1002/wnan.1181
Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release Off J Control Release Soc. March 1, 2000; 65(1-2):133-48. https://doi.org/10.1016/S0168-3659(99)00246-1
Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. February 2014; 39(2):268-307. https://doi.org/10.1016/j.progpolymsci.2013.07.005
Kaur, D., Jain, K., Mehra, N. K., Kesharwani, P., & Jain, N. K. A review on comparative study of PPI and PAMAM dendrimers. Journal of Nanoparticle Research, 2016; 18(6):146. https://doi.org/10.1007/s11051-016-3423-0
Bodewein L, Schmelter F, Fiore S Di, Hollert H, Fischer R, Fenske M. Differences in toxicity of anionic and cationic PAMAM and PPI dendrimers in zebrafish embryos and cancer cell line. Toxicol Appl Pharmacol [Internet]. 2016; https://doi.org/10.1016/j.taap.2016.06.008
Rivas M. Nuevas aplicaciones de los dendrímeros en el campo de la biomedicina. 2018; 14-6.
Santos A, Veiga F, Figueiras A. Dendrimers as Pharmaceutical Excipients : Synthesis, Properties , Toxicity and Biomedical Applications. 2019. https://doi.org/10.3390/ma13010065
Hidalgo S. Síntesis, estudio y caracterización de dendrímeros anfífilos tipo Jano como nanotransportadores de fármacos contra la tuberculosis: toxicidad y actividad antimicrobiana. 2018.
Diaz C, Benitez C, Vidal F, Barraza LF, Jiménez VA, Guzman L, et al. Cytotoxicity and in vivo plasma kinetic behavior of surface-functionalized PAMAM dendrimers. Nanomedicine Nanotechnology, Biol Med [Internet]. 2018; 14(7):2227-34. https://doi.org/10.1016/j.nano.2018.07.005
Thanh VM, Nguyen TH, Tran TV, Ngoc UP, Ho MN, Nguyen TT, et al. Low systemic toxicity nanocarriers fabricated from heparin-mPEG and PAMAM dendrimers for controlled drug release. Mater Sci Eng C [Internet]. 2017; https://doi.org/10.1016/j.msec.2017.07.051
Pedraza, E., García, J., Trejo, M. Capítulo de Estudio: Farmacocinética. Taller de Farmacocinética II. 2020. Available at: SSRN: https://ssrn.com/abstract=3556296 https://doi.org/10.2139/ssrn.3556296
Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. April 1, 2001; 6(8):427-36. https://doi.org/10.1016/S1359-6446(01)01757-3
Wu, L., Ficker, M., Christensen, J., Trohopoulos, P., Moghimi, S. Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. Bioconjug. Chem. 2015; 26(7):1198-211. https://doi.org/10.1021/acs.bioconjchem.5b00031
Yellepeddi, V. K., & Ghandehari, H. Pharmacokinetics of oral therapeutics delivered by dendrimer-based carriers. Expert Opinion on Drug Delivery, 2019; 16(10):1051-1061. https://doi.org/10.1080/17425247.2019.1656607
Shilpa, G., Parbati, B. Effects on pH on Size and Internal Structure of Poly (propylene imine) Dendrimers: A Molecular Dynamics Simulation Study. The Journal of Physical Chemistry. 2018; 122(39):9250-9263. https://doi.org/10.1021/acs.jpcb.8b04653
Kumari, A., Singla, R., Guliani, A., & Yadav, S. K. Nanoencapsulation for drug delivery. EXCLI journal, 2014; 13:265-286. Available from: https://pubmed.ncbi.nlm.nih.gov/26417260/
Choudhary S, Gupta L, Rani S, Dave K, Gupta U. Impact of Dendrimers on Solubility of Hydrophobic Drug Molecules. Front. Pharmacol. 2017; 8:261. https://doi.org/10.3389/fphar.2017.00261
Guldrís, Noeliz. (2018). Preparación de Micelas PIC dendríticas sensibles a pH: estudio de su estabilidad, citotoxicidad e internalización celular. https://core.ac.uk/download/pdf/75994152.pdf
Gupta U, Agashe HB, Asthana A, Jain NK. A review of in vitro-in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomedicine Nanotechnol Biol Med. junio de 2006; 2(2):66-73. https://doi.org/10.1016/j.nano.2006.04.002
Pandita D, Poonia N, Kumar S, Lather V, Madaan K. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014; 6(3):139. https://doi.org/10.4103/0975-7406.130965
Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. March 2009; 71(3):445-62. https://doi.org/10.1016/j.ejpb.2008.09.023
Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. December 22, 2015; 11:1-12. https://doi.org/10.2147/IJN.S93069
Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci. January 2008; 97(1):123-43. https://doi.org/10.1002/jps.21079
Ye T, Yuan K, Zhang W, Song S, Chen F, Yang X, et al. Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci. August 2013; 8(4):207-17. https://doi.org/10.1016/j.ajps.2013.09.002
Nieto MP, Antón IB. Innovaciones en las formulaciones de administración tópica oftálmica. REDUCA. 2012; 4(10). Available at: http://www.revistareduca.es/index.php/reduca/article/view/1081
Achury DM, Achury LF, Rodríguez SM, Álvarez JCD. Fundamentos enfermeros en el proceso de administración de medicamentos. Edtitorial Pontificia Universidad Javeriana; 2012. 876 p. https://doi.org/10.2307/j.ctv893h3t
idUS - Pérdida de agudeza visual por preparados oftálmicos en pacientes usuarios de lentes de contacto [Internet]. [citado 21 de diciembre de 2020]. Disponible en: https://idus.us.es/handle/11441/65159?
Bravo-Osuna I, Herrero-Vanrell R. Potencial de dendrímeros como vehículos de fármacos en Oftalmología. Arch Soc Esp Oftalmol. febrero de 2007; 82(2):69-70. https://doi.org/10.4321/S0365-66912007000200002
CAP06.pdf [Internet]. [citado 21 de diciembre de 2020]. Disponible en: https://www.sefh.es/bibliotecavirtual/fhtomo2/CAP06.pdf
mim065j.pdf [Internet]. [citado 21 de diciembre de 2020]. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2006/mim065j.pdf
Pilloff MG, Migliori ML, Ghiringhelli PD. Reseñas de ingeniería genética [Internet]. Editorial de la Universidad Nacional de Quilmes; 2000 [citado 29 de diciembre de 2020]. Disponible en: http://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=3215533
Cid FAV. Estudio de la internalización celular y potencial uso como nanotransportadores de fármacos de dendrímeros PAMAN en neuronas. :105.
Liu M, Fréchet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technol Today. octubre de 1999; 2(10):393-401. https://doi.org/10.1016/S1461-5347(99)00203-5
Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. September 2012; 64(5):1020-37. https://doi.org/10.1016/S1734-1140(12)70901-5
Kannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med. December 2014; 276(6):579-617 https://doi.org/10.1111/joim.12280
Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev. June 21, 2009; 61(6):457-66. https://doi.org/10.1016/j.addr.2009.03.010
Published
Abstract Display: 719 
PDF Downloads: 817 PDF Downloads: 62 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.